OncoGenex Waits, and Waits, For Data on Prostate Cancer Drug
03:05 EDT 2 Aug 2012 | Xconomy
Pity Scott Cormack. As the CEO of an aspiring prostate cancer drug developer, he’s got to answer to the masters at the FDA and the cancer physicians who want unequivocal, long-term data to prove his company’s product works. His other masters, tho..
Original Article: OncoGenex Waits, and Waits, For Data on Prostate Cancer Drug
More From BioPortfolio on "OncoGenex Waits, and Waits, For Data on Prostate Cancer Drug"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
